Prof. Pfützner has been a central contributor to the development of Lifecare’s technology platform and has worked closely with the Company for more than nine years. The Company appreciates his significant contributions to the scientific and technological development of Lifecare’s implantable glucose monitoring technology.

Lifecare is grateful that Prof. Pfützner has agreed to continue contributing to the Company in an operational and supporting role. The Company will evaluate how to best make use of his extensive scientific expertise, deep knowledge of Lifecare’s technology, and valuable insights into the diabetes technology market going forward.

“Over the past nine years, Andreas has played a pivotal role in shaping Lifecare’s scientific foundation. His medical expertise, scientific leadership and deep understanding of the diabetes technology field have been instrumental in advancing our implantable CGM technology from concept to the stage we are at today. On behalf of the Company and the Board, I would like to express my sincere gratitude for his dedication and contributions to Lifecare,” said Joacim Holter, CEO of Lifecare ASA.

“As Lifecare now moves further into a phase increasingly focused on product development, industrialization and preparation for market entry, the nature of our operational priorities is evolving. We are therefore particularly pleased that Andreas will continue to support the Company with his medical insight and long-standing experience with our technology and the broader diabetes technology landscape.”

The Company will initiate a process to ensure continued leadership of its scientific activities.